IRONWOOD PHARMACEUTICALS, INC. Income Tax Expense
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Income Tax Expense of $22.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2026-06-30 was $22.44M, a 57.77% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2026-03-31 was $24.40M, a 2090.22% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2025-12-31 was $2.73M, a 87.44% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2025-09-30 was $27.94M, a 103.60% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2025 was $46.01M, a 28.47% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2024 was $64.32M, a 22.96% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2023 was $83.49M, a 7.93% increase from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2022 was $77.36M.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.44M 10-Q · filed 2026-08-06 | $46.84M 10-Q · filed 2026-08-06 | $49.57M derived: sum of 3 quarters · filed 2026-08-06 | $77.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $24.40M 10-Q · filed 2026-05-07 | $27.13M derived: sum of 2 quarters · filed 2026-05-07 | $55.07M derived: sum of 3 quarters · filed 2026-05-07 | $69.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $30.67M derived: sum of 2 quarters · filed 2026-02-26 | $44.89M derived: sum of 3 quarters · filed 2026-08-06 | $46.01M 10-K · filed 2026-02-26 |
| 2025-09-30 | $27.94M 10-Q · filed 2025-11-10 | $42.16M derived: sum of 2 quarters · filed 2026-08-06 | $43.28M 10-Q · filed 2025-11-10 | $65.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $14.22M 10-Q · filed 2026-08-06 | $15.34M 10-Q · filed 2026-08-06 | $37.08M derived: sum of 3 quarters · filed 2026-08-06 | $50.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.11M 10-Q · filed 2026-05-07 | $22.85M derived: sum of 2 quarters · filed 2026-05-07 | $36.58M derived: sum of 3 quarters · filed 2026-05-07 | $56.31M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $21.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $35.46M derived: sum of 2 quarters · filed 2026-02-26 | $55.20M derived: sum of 3 quarters · filed 2026-02-26 | $64.32M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.72M 10-Q · filed 2025-11-10 | $33.46M derived: sum of 2 quarters · filed 2025-11-10 | $42.58M 10-Q · filed 2025-11-10 | $74.68M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $19.74M 10-Q · filed 2025-08-11 | $28.86M 10-Q · filed 2025-08-11 | $60.96M derived: sum of 3 quarters · filed 2025-08-11 | $78.94M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $9.12M 10-Q · filed 2025-05-12 | $41.23M derived: sum of 2 quarters · filed 2025-05-12 | $59.21M derived: sum of 3 quarters · filed 2025-05-12 | $72.46M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $32.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $50.09M derived: sum of 2 quarters · filed 2025-03-31 | $63.34M derived: sum of 3 quarters · filed 2025-03-31 | $83.49M 10-K · filed 2025-03-31 |
| 2023-09-30 | $17.98M 10-Q · filed 2024-11-07 | $31.24M derived: sum of 2 quarters · filed 2024-11-07 | $51.38M 10-Q · filed 2024-11-07 | $74.78M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $13.26M 10-Q · filed 2024-08-08 | $33.40M 10-Q · filed 2024-08-08 | $56.80M derived: sum of 3 quarters · filed 2025-03-31 | $76.39M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $20.15M 10-Q · filed 2024-05-09 | $43.55M derived: sum of 2 quarters · filed 2025-03-31 | $63.13M derived: sum of 3 quarters · filed 2025-03-31 | $79.84M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $23.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $42.99M derived: sum of 2 quarters · filed 2025-03-31 | $59.69M derived: sum of 3 quarters · filed 2025-03-31 | $77.36M 10-K · filed 2025-03-31 |
| 2022-09-30 | $19.59M 10-Q · filed 2023-11-09 | $36.30M derived: sum of 2 quarters · filed 2023-11-09 | $53.96M 10-Q · filed 2023-11-09 | $58.84M derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | $16.70M 10-Q · filed 2023-08-09 | $34.37M 10-Q · filed 2023-08-09 | $39.25M derived: sum of 3 quarters · filed 2024-02-16 | $43.08M derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | $17.66M 10-Q · filed 2023-05-04 | $22.55M derived: sum of 2 quarters · filed 2024-02-16 | $26.37M derived: sum of 3 quarters · filed 2024-02-16 | -$310.56M derived: sum of 4 quarters · filed 2024-02-16 |
| 2021-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $8.71M derived: sum of 2 quarters · filed 2024-02-16 | -$328.22M derived: sum of 3 quarters · filed 2024-02-16 | -$327.79M 10-K · filed 2024-02-16 |
| 2021-09-30 | $3.83M 10-Q · filed 2022-11-03 | -$333.10M derived: sum of 2 quarters · filed 2022-11-03 | -$332.67M 10-Q · filed 2022-11-03 | -$331.38M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | -$336.93M 10-Q · filed 2022-08-04 | -$336.50M 10-Q · filed 2022-08-04 | -$335.20M derived: sum of 3 quarters · filed 2023-02-16 | -$333.81M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | $432.00K 10-Q · filed 2022-05-05 | $1.73M derived: sum of 2 quarters · filed 2023-02-16 | $3.12M derived: sum of 3 quarters · filed 2023-02-16 | $3.12M derived: sum of 4 quarters · filed 2023-02-16 |
| 2020-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $2.69M derived: sum of 2 quarters · filed 2023-02-16 | $2.69M derived: sum of 3 quarters · filed 2023-02-16 | $2.69M 10-K · filed 2023-02-16 |
| 2020-09-30 | $1.39M 10-Q · filed 2021-11-04 | $1.39M derived: sum of 2 quarters · filed 2021-11-04 | $1.39M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | $0.00 10-K · filed 2021-02-17 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-17 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-25 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-22 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-02-22 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-07 | $3.00K derived: sum of 2 quarters · filed 2014-02-07 | $3.00K 10-K · filed 2014-02-07 | |
| 2011-09-30 | $3.00K 10-Q · filed 2012-11-06 | $3.00K 10-Q · filed 2012-11-06 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | -$2.94M derived: sum of 2 quarters · filed 2013-02-21 | -$2.94M 10-K · filed 2013-02-21 | |
| 2010-09-30 | -$2.94M 10-Q · filed 2011-11-09 | -$2.94M 10-Q · filed 2011-11-09 | ||
| 2009-12-31 | -$296.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |